FR2611707B1 - Nouveau carbamate de phenyle, sa preparation et son utilisation comme medicament - Google Patents

Nouveau carbamate de phenyle, sa preparation et son utilisation comme medicament

Info

Publication number
FR2611707B1
FR2611707B1 FR888802597A FR8802597A FR2611707B1 FR 2611707 B1 FR2611707 B1 FR 2611707B1 FR 888802597 A FR888802597 A FR 888802597A FR 8802597 A FR8802597 A FR 8802597A FR 2611707 B1 FR2611707 B1 FR 2611707B1
Authority
FR
France
Prior art keywords
medicament
preparation
phenyl carbamate
novel phenyl
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR888802597A
Other languages
English (en)
French (fr)
Other versions
FR2611707A1 (fr
Inventor
Albert Enz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6322236&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2611707(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of FR2611707A1 publication Critical patent/FR2611707A1/fr
Application granted granted Critical
Publication of FR2611707B1 publication Critical patent/FR2611707B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/44—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
FR888802597A 1987-03-04 1988-02-29 Nouveau carbamate de phenyle, sa preparation et son utilisation comme medicament Expired - Lifetime FR2611707B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3706914 1987-03-04

Publications (2)

Publication Number Publication Date
FR2611707A1 FR2611707A1 (fr) 1988-09-09
FR2611707B1 true FR2611707B1 (fr) 1990-04-20

Family

ID=6322236

Family Applications (1)

Application Number Title Priority Date Filing Date
FR888802597A Expired - Lifetime FR2611707B1 (fr) 1987-03-04 1988-02-29 Nouveau carbamate de phenyle, sa preparation et son utilisation comme medicament

Country Status (29)

Country Link
US (1) US5602176A (enExample)
JP (3) JP2625478B2 (enExample)
KR (1) KR0133686B1 (enExample)
AT (1) AT394190B (enExample)
AU (1) AU618949B2 (enExample)
BE (1) BE1001467A3 (enExample)
CA (1) CA1307003C (enExample)
CH (1) CH675720A5 (enExample)
CS (1) CS411091A3 (enExample)
CY (1) CY1735A (enExample)
DK (1) DK175762B1 (enExample)
ES (1) ES2010527A6 (enExample)
FI (1) FI89165C (enExample)
FR (1) FR2611707B1 (enExample)
GB (1) GB2203040C (enExample)
GR (1) GR1000023B (enExample)
HK (1) HK110093A (enExample)
HU (1) HU201906B (enExample)
IE (1) IE61714B1 (enExample)
IL (1) IL85609A (enExample)
IT (1) IT1219853B (enExample)
LU (2) LU87150A1 (enExample)
MY (1) MY103225A (enExample)
NL (1) NL195004C (enExample)
NZ (1) NZ223714A (enExample)
PT (1) PT86875B (enExample)
SA (1) SA93140384B1 (enExample)
SE (1) SE8800731A0 (enExample)
ZA (1) ZA881584B (enExample)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU201906B (en) * 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
US5712282A (en) * 1994-04-15 1998-01-27 Masaomi Iyo Method for therapeutically treating tardive dyskinesia and uses thereof
US6251938B1 (en) 1996-12-18 2001-06-26 Teva Pharmaceutical Industries, Ltd., Phenylethylamine derivatives
AU5620998A (en) * 1996-12-18 1998-07-15 Technion Research & Development Foundation Ltd. Phenylethylamine derivatives
HU229507B1 (en) 1996-12-18 2014-01-28 Technion Res & Dev Foundation 1,2,3,4-tetrahydro-amino-naphtalenyl- and aminoindan derivatives and pharmaceutical compositions comprising them
US6316023B1 (en) * 1998-01-12 2001-11-13 Novartis Ag TTS containing an antioxidant
GB9800526D0 (en) * 1998-01-12 1998-03-11 Ciba Geigy Ag Organic compounds
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
WO2000019985A2 (en) 1998-10-01 2000-04-13 Novartis Ag New sustained release oral formulations
US20040209849A1 (en) * 1998-11-27 2004-10-21 Sanochemia Pharmazeutika Aktiengesellschaft Use of effectors of the central cholinergic nervous system for treatment of delirium
WO2000033840A1 (en) * 1998-12-11 2000-06-15 Bonnie Davis Use of acetylcholinesterase inhibitors on the modulation of the hypothalamic-pituitary-gonadal axis
GB9923045D0 (en) * 1999-09-29 1999-12-01 Novartis Ag New oral formulations
US6534541B1 (en) 1999-10-19 2003-03-18 Novartis Ag Treatment of ocular disorders
AU2001257022B2 (en) * 2000-04-13 2005-02-03 Mayo Foundation For Medical Education And Research Abeta 42 lowering agents
US20040010038A1 (en) * 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
CZ20023555A3 (cs) 2002-10-24 2004-01-14 Léčiva, A.S. Způsob výroby (-)-(S)-3-[1-(dimethylamino)ethyl]fenyl-N-ethyl-N-methylkarbamátu
WO2004037234A2 (en) * 2002-10-24 2004-05-06 Merz Pharma Gmbh & Co. Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
WO2005065069A2 (en) * 2003-07-11 2005-07-21 Myriad Genetics, Inc. Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
JP4676961B2 (ja) * 2003-10-21 2011-04-27 コルシド・ファーマシューティカルズ・インコーポレイテッド コリンエステラーゼを阻害し、薬理活性物質を放出するカルバモイルエステル類
GB2409453A (en) * 2003-12-24 2005-06-29 Generics Process for the preparation of aminoalkyl phenylcarbamates
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
EP1745180A1 (en) * 2004-04-29 2007-01-24 Keystone Retaining Wall Systems, Inc. Veneers for walls, retaining walls and the like
EP1779867A4 (en) * 2004-07-01 2009-12-02 Eisai R&D Man Co Ltd MEANS FOR PROMOTING NERVE REVENERATION
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
CA2618985A1 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
EP1856036B1 (en) * 2004-11-08 2016-12-14 Emcure Pharmaceuticals Limited An efficient method for preparation of (s)-3-[(1-dimethyl amino)ethyl]-phenyl-n-ethyl-n-methyl-carbamate
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
US20070042034A1 (en) * 2005-07-22 2007-02-22 Myriad Genetics, Incorporated High drug load formulations and dosage forms
ES2267399B1 (es) 2005-08-04 2008-02-01 Ragactives, S.L. Procedimiento para la obtencion de carbamatos de fenilo.
ATE543545T1 (de) 2005-09-15 2012-02-15 Sony Computer Entertainment Inc Beschaffung einer eingabe zum kontrollieren der ausführung eines spielprogrammes
TWI389709B (zh) * 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
CN103142570A (zh) * 2005-12-09 2013-06-12 耶路撒冷希伯来大学伊森姆研究发展公司 低剂量Ladostigil 用于神经保护的用途
TW200744576A (en) * 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
US7767843B2 (en) * 2006-03-02 2010-08-03 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
EP2046119A2 (en) * 2006-07-07 2009-04-15 Myriad Genetics, Inc. Treatment of psychiatric disorders
ATE472523T1 (de) * 2006-08-17 2010-07-15 Alembic Ltd Verbessertes verfahren zur herstellung von rivastigmin
WO2008037433A1 (en) 2006-09-29 2008-04-03 Synthon B.V. Process for making aminoalkylphenyl carbamates and intermediates therefor
ATE549021T1 (de) 2006-10-27 2012-03-15 Medivation Neurology Inc Kombinationstherapien zur behandlung von morbus alzheimer mit dimebon und donepezil
EP1942100A1 (en) * 2007-01-04 2008-07-09 Krka Tovarna Zdravil, D.D., Novo Mesto Amorphous and crystalline forms of rivastigmine hydrogentartrate
EP2125709A2 (en) * 2007-02-02 2009-12-02 Colucid Pharmaceuticals, Inc. Compounds that inhibit cholinesterase
EP1980552A3 (en) 2007-04-10 2008-10-29 Dr. Reddy's Laboratories Ltd. A process for the preparation of rivastigmine or a salt thereof
WO2008124969A1 (en) * 2007-04-16 2008-10-23 Topharman Shanghai Co., Ltd. Preparation method of rivastigmine and its intermediates
US7884121B2 (en) * 2007-06-11 2011-02-08 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
JP2010533717A (ja) * 2007-07-18 2010-10-28 コルシド・ファーマシューティカルズ・インコーポレイテッド 覚醒を促進する方法
US8593728B2 (en) * 2009-02-19 2013-11-26 Toyota Motor Engineering & Manufacturing North America, Inc. Multilayer photonic structures
US20090082436A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched rivastigmine
CN101910110B (zh) * 2008-01-10 2013-05-22 上海医药工业研究院 利凡斯的明的制备方法、其中间体以及中间体的制备方法
US8420846B2 (en) 2008-08-25 2013-04-16 Jubilant Life Sciences Limited Process for producing (S)-3-[(1-dimethylamino)ethyl] phenyl-N-ethyl-N-methyl-carbamate via novel intermediates
US20100087768A1 (en) * 2008-10-02 2010-04-08 Forlano Paula Transdermal drug delivery system for liquid active ingredient
GB0823554D0 (en) 2008-12-24 2009-01-28 Novartis Ag Process for the preparation of optically active compounds using transfer hydrogenation
CN101823970B (zh) * 2009-03-03 2013-05-08 江苏恩华药业股份有限公司 卡巴拉汀及其中间体的合成方法
US10076502B2 (en) 2009-12-22 2018-09-18 Luye Pharma Ag Transdermal therapeutic system for administering rivastigmine or derivatives thereof
WO2011076621A2 (de) 2009-12-22 2011-06-30 Acino Ag Transdermales therapeutisches system zur verabreichung von rivastigmin oder dessen derivaten
ES2363395B1 (es) * 2010-01-20 2012-02-23 Farmalider, S.A. Composición farmacéutica l�?quida de rivastigmina o de una de sus sales de adición de �?cido para la administración por v�?a oral.
WO2011100373A1 (en) * 2010-02-09 2011-08-18 The Johns Hopkins University Methods and compositions for improving cognitive function
TW201138805A (en) 2010-03-29 2011-11-16 Novartis Ag Composition of organic compounds
WO2011151669A1 (en) 2010-06-02 2011-12-08 Jubilant Life Sciences Limited Process for producing enantiomerically enriched isomer of 3-(1-aminoethyl) phenyl derivative and employing the same to produce rivastigmine or its pharmaceutically acceptable salt
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
HUE038434T2 (hu) 2010-06-17 2018-10-29 Codexis Inc Biokatalizátorok és módszerek (S)-3(1-aminoetil)-fenol szintéziséhez
JP5916746B2 (ja) 2010-11-15 2016-05-11 エージンバイオ， インコーポレイテッド 認知障害を処置するためのピリダジン誘導体、組成物、および方法
ES2545094T3 (es) 2010-12-14 2015-09-08 Acino Ag Sistema terapéutico transdérmico para la administración de un principio activo
CN102786441B (zh) 2011-05-18 2013-11-13 浙江海正药业股份有限公司 利凡斯的明的制备方法、其中间体以及中间体的制备方法
EP2711002A4 (en) 2011-05-20 2014-10-29 Sk Chemicals Co Ltd PLASTER WITH RIVASTIGMIN
AR082640A1 (es) * 2011-08-25 2012-12-19 Amarin Technologies S A Un dispositivo para la administracion transdermal de compuestos alcalinos susceptibles a la degradacion en su forma no salificada
CN103796645B (zh) 2011-08-31 2017-06-20 东洋油墨Sc控股株式会社 贴剂
CN103073456B (zh) * 2011-10-26 2014-03-19 连云港润众制药有限公司 重酒石酸卡巴拉汀中间体的制备方法
EP2594261A1 (en) 2011-11-18 2013-05-22 Labtec GmbH Composition for transdermal administration of rivastigmine
WO2013142339A1 (en) 2012-03-23 2013-09-26 Novartis Ag Transdermal therapeutic system and method
ES2449215B1 (es) * 2012-09-17 2014-07-14 Galenicum Health S.L. Solución oral de (S)-3-[1-(dimetilamino)etil]fenil N-etil-N-metilcarbamato
KR20140038237A (ko) 2012-09-20 2014-03-28 에스케이케미칼주식회사 리바스티그민의 안정성이 개선된 의약품
HK1215170A1 (zh) 2012-11-14 2016-08-19 The Johns Hopkins University 治療精神分裂症的方法和組合物
CN103896787A (zh) * 2012-12-26 2014-07-02 江苏康倍得药业有限公司 一种卡巴拉汀前体[1-(3-甲氧基苯基)乙基]二甲胺的制备方法
WO2014111790A2 (en) 2013-01-15 2014-07-24 Zydus Technologies Limited Stable transdermal pharmaceutical drug delivery system comprising rivastigmine
EP2968237A4 (en) 2013-03-15 2016-08-31 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
US11160785B2 (en) 2013-03-15 2021-11-02 Agenebio Inc. Methods and compositions for improving cognitive function
CN103319374B (zh) * 2013-06-09 2015-04-22 无锡佰翱得生物科学有限公司 一种(s)-卡巴拉汀的不对称合成方法
EP3033082B1 (en) 2013-08-16 2021-06-16 Universiteit Maastricht Treatment of cognitive impairment with pde4 inhibitor
AU2014368961B2 (en) 2013-12-20 2019-10-17 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
HK1251980B (en) 2015-05-22 2020-07-10 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
IL256354B (en) 2015-06-19 2022-09-01 Agenebio Inc Benzodiazepine derivatives, compositions, and uses thereof for treating cognitive impairment
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
EP3810611A4 (en) 2018-06-19 2022-03-30 Agenebio, Inc. BENZODIAZEPIN DERIVATIVES, COMPOSITIONS AND METHODS FOR THE TREATMENT OF COGNITIVE DISORDERS
KR20200035359A (ko) 2018-09-26 2020-04-03 캐딜라 파마슈티클즈 리미티드 리바스티그민 제조용 중간체의 합성
CN120584115A (zh) 2022-08-19 2025-09-02 艾吉因生物股份有限公司 苯并氮杂䓬衍生物、组合物和用于治疗认知损害的方法
WO2025038382A1 (en) 2023-08-11 2025-02-20 Momentive Performance Materials Inc. Pharmaceutical adhesive compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4469700A (en) * 1981-06-19 1984-09-04 Lowell M. Somers Benzoylecgonine or benzoylnorecgonine as active agents for the treatment of rheumatoid arthritis
IL74497A (en) * 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
HU201906B (en) * 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
FI89165B (fi) 1993-05-14
JPH09165362A (ja) 1997-06-24
JPS63238054A (ja) 1988-10-04
GR880100125A (en) 1989-01-31
SA93140384B1 (ar) 2006-04-04
JPH09118617A (ja) 1997-05-06
FI880972L (fi) 1988-09-05
FI880972A0 (fi) 1988-03-02
CH675720A5 (enExample) 1990-10-31
GR1000023B (el) 1990-01-31
DK112588A (da) 1988-09-05
DK175762B1 (da) 2005-02-14
US5602176A (en) 1997-02-11
SE8800731L (sv) 1988-09-05
IE880583L (en) 1988-09-04
FI89165C (fi) 1993-08-25
ES2010527A6 (es) 1989-11-16
DK112588D0 (da) 1988-03-02
GB2203040C (en) 2014-07-30
IL85609A0 (en) 1988-08-31
GB2203040A (en) 1988-10-12
JP2859225B2 (ja) 1999-02-17
IE61714B1 (en) 1994-11-30
CS411091A3 (en) 1992-12-16
AU618949B2 (en) 1992-01-16
ZA881584B (en) 1989-11-29
LU87150A1 (fr) 1988-11-17
BE1001467A3 (fr) 1989-11-07
FR2611707A1 (fr) 1988-09-09
IT8847693A0 (it) 1988-03-04
ATA55188A (de) 1991-08-15
MY103225A (en) 1993-05-29
AU1255488A (en) 1988-09-08
GB8804888D0 (en) 1988-03-30
SE8800731D0 (sv) 1988-03-02
KR0133686B1 (ko) 1998-04-21
NL195004B (nl) 2003-07-01
JP2625478B2 (ja) 1997-07-02
HK110093A (en) 1993-10-29
HU201906B (en) 1991-01-28
NZ223714A (en) 1994-05-26
LU90297I2 (fr) 1998-12-07
CA1307003C (en) 1992-09-01
PT86875B (pt) 1992-05-29
KR880011088A (ko) 1988-10-26
SE8800731A0 (sv) 1988-09-05
HUT49325A (en) 1989-09-28
NL8800436A (nl) 1988-10-03
NL195004C (nl) 2003-11-04
CY1735A (en) 1994-06-03
GB2203040B (en) 1990-10-24
IT1219853B (it) 1990-05-24
PT86875A (pt) 1988-04-01
AT394190B (de) 1992-02-10
IL85609A (en) 1992-07-15

Similar Documents

Publication Publication Date Title
FR2611707B1 (fr) Nouveau carbamate de phenyle, sa preparation et son utilisation comme medicament
DK305387A (da) Konfektureblanding med bloed tekstur, indeholdende fibre
IL83016A0 (en) Alkylenediamines,their preparation and their use as insecticides
FR2551064B1 (fr) Nouveaux esters et amides aromatiques, leur preparation et leur utilisation comme medicaments
IL56405A0 (en) Novel substituted n-pehnyl-n'-(2-chloro-6-fluoro-benzoyl)-ureas, their preparation and their use as insecticides
BE882632A (fr) Substance antibiotique a/16686, sa preparation et son utilisation
ZA872454B (en) Colourless ketimines,their preparation and their use as crosslinking agent
BE879170A (fr) Nouvel antibiotique sb-72310, sa preparation et son utilisation
FR2560196B1 (fr) Nouvelles 8a-acylaminoergolines, leur preparation et leur utilisation comme medicaments
ATA76889A (de) Viskosekupplung
EG13096A (en) Novel phenyl carbamoyl-2-pyrazolines and their use as insecticides
FR2610932B1 (fr) Nouvel acide piperazinecarboxylique, sa preparation et son utilisation comme medicament
JPS5615280A (en) Novel nncarboxylated carbamate* its manufacture and its use as insecticide
BE885929A (fr) Compositions catalytiques a base de cuivre, leur preparation et leur utilisation
BE862971A (fr) 4'-desoxyvincristine et composes apparentes, et leur utilisation comme medicaments
BE884661A (fr) Nouvelles 3-amino-oxazolidine-2-ones, leur preparation et leur utilisation comme agents fongicides
IL52300A0 (en) Novel carbamic acid oxime-esters their preparation and their use as fungicides
FR2617166B1 (fr) Nouvelle 8a-acylaminoergoline, sa preparation et son utilisation comme medicament
FR2612185B1 (fr) Derives oxo-isoindolinyliques optiquement actifs, leur preparation et leur utilisation comme medicaments
FR2607810B1 (fr) Nouveaux derives azoliques, leur preparation et leur utilisation comme medicaments
FR2609715B1 (fr) Nouveaux diazepinoindoles, leur preparation et leur utilisation comme medicaments
IL47472A (en) N-sulphenylated 2,2-dimethyl-benzo-1,3-dioxolan-4-yl phenyl carbamates,their preparation and their use as insecticides
IL84764A0 (en) Substituted benzamides,their preparation and their use as pesticides
BE896421A (fr) Nouvelles indole-alkyleneamines substitueees, leur preparation et leur utilisation comme medicaments
JPS54148774A (en) Novel nncarboxylated carbamate*its preparation and its use as insecticide

Legal Events

Date Code Title Description
TP Transmission of property
CP Supplementary protection certificate (spc) filed

Free format text: PRODUCT NAME: RIVASTIGMINE; HYDROGENOTARTRATE; NAT. REGISTRATION NO/DATE: EU/1/98/066/001 19980512;FIRST REGISTRATION: LI - 54275 19970731

Spc suppl protection certif: 98C0033

Filing date: 19981002

CR Request for supplementary protection certificate laid open to the public (eec regulation of 18 june 1992)

Free format text: 98C0033, 19981002

CP Supplementary protection certificate (spc) filed
CY Supplementary certificate of protection granted (eec regulation of 18 june 1992)

Free format text: 98C0033, 981002, EXPIRES: 20120731

CL Concession to grant licences

Spc suppl protection certif: 98C0033